Acer Therapeutics and its Swiss partner Relief Therapeutics celebrated an FDA approval on Tuesday for Olpruva, an oral drug for urea cycle disorders (UCDs).
The news comes roughly six months after regulators rejected Olpruva, also known as ACER-001, because its contract packaging manufacturer wasn
